AstraZeneca's High-level Results From ADJUVANT Br.31 Phase 3 Trial Of Imfinzi Did Not Achieve Statistical Significance For Primary Endpoint Of Disease-free Survival Versus Placebo In Early-stage Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's Phase 3 trial of Imfinzi in early-stage non-small cell lung cancer did not achieve statistical significance for the primary endpoint of disease-free survival compared to placebo.
June 25, 2024 | 9:02 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca's Phase 3 trial of Imfinzi in early-stage non-small cell lung cancer did not achieve statistical significance for the primary endpoint of disease-free survival compared to placebo.
The failure to achieve statistical significance in the primary endpoint of disease-free survival for Imfinzi in the Phase 3 trial is likely to negatively impact AstraZeneca's stock price in the short term. Investors may react to the news as it suggests a setback in the development of a key cancer treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100